Reforgene Biosciences Secures Hundreds of Millions RMB in Series A+ Financing to Advance Gene Editing Therapies into Clinical Trials

VCBeat has learned that Rayfulgen, a leading domestic gene-editing therapy company, has successfully completed an A+ financing round worth hundreds of millions of RMB. The round was led by Yansheng Ventures, with participation from Sinovation Ventures, Boyuan Capital, China Merchants Securities Investment, and Everbright Limited, among others. Joywise Capital served as the exclusive financial advisor for this financing round. The funds will primarily be used to advance early-stage products into clinical trials and to support the systematic development of its pipeline.

Gene editing technology has brought about innovations in biomedicine that far exceed expectations, and it remains in an early stage of development globally. Gene editing drugs target the human genetic code, featuring high programmability and platform-based characteristics. RayWind Bio is a leading R&D enterprise in this field with a global perspective. Founded in Guangzhou in 2019, the company is committed to providing patients with truly curative therapeutic options. Its founding team consists of renowned scientists in gene editing and serial entrepreneurs.

Driven by technological innovation, Ruifeng has expanded its R&D pipeline from monogenic genetic disorders—including thalassemia, which affects the largest global population—to major common diseases. The company boasts nearly 7,000 square meters of R&D facilities and pilot-scale production workshops. Ruifeng Biologics has also developed a digital gene therapy innovation platform that integrates multi-layered technological capabilities, including genomic big data, bioinformatics, machine learning, and downstream validation systems. Compared with traditional drug development platforms, it demonstrates strong cross-disciplinary innovative strength and holds unicorn potential in the field of gene-editing therapies.

Dr. Liang Junbin, Founder of Ruifeng BiotechWe are deeply honored to have earned the recognition and support of top-tier investment institutions. As an early pioneer in the field of gene-editing therapeutics, RayWind has achieved rapid growth, reaching milestone results across multiple pipeline areas. Our early-stage development pipeline is poised to enter clinical trials, with preclinical data for multiple indications demonstrating significant efficacy and a favorable safety profile. We firmly believe that this revolutionary technology holds the potential to profoundly transform patients’ lives. New drug development demands long-term resilience and patience. We extend our gratitude to both new and existing investors, as this round of financing continues to inject robust capital momentum into RayWind’s growth. We will remain steadfast in our mission to “Innovate for Life,” developing curative gene therapies for patients.

Mr. Chen Jie, Founding Partner of Yuansheng VenturesHe stated that since the third-generation gene-editing technology CRISPR/Cas9 achieved gene editing in human cells in 2013, there has been active global exploration of the clinical applications of CRISPR/Cas technology. He expressed delight at the positive proof-of-concept (POC) clinical results achieved by CRISPR Therapeutics’ ex vivo autologous hematopoietic stem cell gene-editing therapy for β-thalassemia, and by Intellia Therapeutics’ in vivo gene-editing therapy for ATTR amyloidosis. He believes that gene therapies utilizing gene-editing technologies hold promise for delivering more durable and superior therapeutic outcomes for patients with genetic disorders and other conditions. RayWind Bio is deeply committed to advancing the clinical application of gene-editing technologies. Co-founder Dr. Huang Junjiu is one of the earliest scientists in China to conduct research on gene-editing therapies for thalassemia, having built a substantial foundation in the field of gene editing. The company’s Founder and CEO, Dr. Liang Junbin, is a serial entrepreneur with extensive experience in corporate management. We look forward to RayWind Bio’s products entering clinical trials as soon as possible to benefit patients.

Mr. Wu Kai, Partner at Sinovation VenturesIt stated that Rayful Bio is a first-tier enterprise in China leveraging gene-editing technology to develop gene therapies. Its founder, Dr. Liang Junbin, is an accomplished serial entrepreneur, and its core team combines extensive entrepreneurial experience with top-tier academic credentials, while also being young and driven. Although Rayful Bio was founded only recently, it has rapidly advanced a series of pipeline candidates to leading positions within a short timeframe, with layouts spanning the hematopoietic system, ophthalmology, respiratory diseases, and the central nervous system. Sinovation Ventures is highly optimistic about the company’s sustained R&D capabilities and believes it will grow into a gene therapy enterprise with international influence.

Mr. Qu Long, Investment Director and Head of the Healthcare Team at China Merchants SecuritiesIt stated that RayWind Bio is a pioneer in the field of gene-editing therapies in China. The company boasts leading-edge technology and an experienced management team. CMS Capital expressed strong confidence in the future of gene-editing therapies and highly recognized RayWind Bio’s R&D capabilities in this field, committing to continue providing support and services for its development.

Ms. Zhang Cheng, Managing Director of the Fund of Funds at China Everbright LimitedHe stated that gene therapy has witnessed rapid development in recent years and is one of the most promising frontier areas in medicine. As a gene-editing therapy company rooted in the Greater Bay Area, RayWind Bio has achieved pioneering results in diseases such as thalassemia. Since establishing the Guangzhou Light Control Guangdong-Hong Kong-Macao Youth Entrepreneurship Fund of Funds in 2019, we have been committed to supporting youth entrepreneurship projects from Guangzhou, Hong Kong, and Macao within the Greater Bay Area. RayWind Bio stands out as an exemplary representative of these youth-led entrepreneurial initiatives. We look forward to Dr. Liang leading his team to accelerate the advancement of their pipeline in development, thereby introducing more innovative therapies for genetic disorders such as thalassemia.

Dr. Li Yishi, Partner at Haoyue CapitalWe are honored to serve as the exclusive financial advisor for RayWind Bio’s latest financing round. Gene editing, represented by CRISPR/Cas9, is a groundbreaking, revolutionary technology that enables therapies to target the root causes of diseases by modifying patients’ genomes to achieve cures. It is also one of the technological fields where China’s development pace most closely aligns with that of overseas markets. RayWind Bio is the only CRISPR technology company in China that has made significant strides in both hematology and ophthalmology. Over the past year, the team has demonstrated exceptional execution capabilities and the strength to overcome industry barriers, making it a scarce and highly sought-after asset in the domestic market. We are optimistic about RayWind Bio’s growth potential and feel privileged to grow alongside such an outstanding enterprise.

ReWind Bio is a leading gene therapy company in China, driven by core gene-editing technologies and dedicated to the development of transformative medicines. Its team comprises internationally renowned scientists in the field of gene editing, returning scholars with research experience at top overseas clinical research institutions, entrepreneurs with successful track records in the gene industry, and senior executives from multinational pharmaceutical companies. As one of the earliest teams globally to apply gene editing for the exploration of genetic disease treatments, ReWind Bio has achieved pioneering results in therapeutic areas such as hematology and ophthalmology. The company has built robust technical capabilities in key areas including innovation in gene-editing tools, drugability strategy analysis, construction of novel animal models, and multi-level efficacy and safety assessments, with two major innovative drug pipelines focusing on in vivo and ex vivo approaches. ReWind Bio’s mission is to provide accessible and curative therapies for patients with severe diseases, leveraging revolutionary gene-editing technologies.

YuanSheng Venture Capital is an investment firm focused on early-stage and growth-stage companies in the healthcare sector. Headquartered in Suzhou BioBAY, it maintains a global reach. The firm currently manages approximately RMB 6 billion in assets and has completed investments in over 100 high-quality projects, primarily spanning new drug development, medical devices, in vitro diagnostics (IVD), and healthcare services. It has delivered substantial investment returns and has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. YuanSheng Venture Capital brings together a team of seasoned professional investors and world-class scientific advisors, possessing extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and related fields. Leveraging its focused strategy and rich industry resources, YuanSheng Venture Capital is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Sinovation Ventures is a technology-focused venture capital firm founded by Dr. Kai-Fu Lee in September 2009. It aims to help young Chinese entrepreneurs build world-class companies through comprehensive startup services and manages dual-currency funds with total assets under management of approximately RMB 17.5 billion. As a leading international service-oriented venture capital firm, Sinovation Ventures primarily focuses on artificial intelligence and hard tech, robotics and automation, chips/semiconductors, enterprise software, healthcare, and other sectors, with a dedicated focus on investing in early- to mid-stage high-growth technology enterprises. To date, it has participated in the investment of approximately 400 projects, nurturing more than 20 unicorn companies. Sinovation Ventures pioneered the “tech investment + artificial intelligence” model and established the Sinovation Ventures AI Institute in September 2016, with Dr. Kai-Fu Lee serving as its dean to comprehensively advance talent development, entrepreneurship, scientific research, and industry integration in the field of artificial intelligence.

BioTrack Capital, established in 2017, is a professional investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. We are not just investors; we are long-term partners to entrepreneurs. We provide sustained support to the most distinguished healthcare founders, cultivating the next generation of leading enterprises in China’s healthcare industry.

China Merchants Securities Investment Co., Ltd. is a wholly-owned alternative investment subsidiary of China Merchants Securities, with a registered capital of RMB 7.1 billion. It primarily engages in equity investments and financial product investments. Guided by value investing principles, the company’s equity investments focus on opportunities in healthcare, new energy and new materials, intelligent manufacturing, technology, and semiconductors, committed to providing investee companies with comprehensive, full-value-chain financial services.

China Everbright Limited (“Everbright Limited”, Stock Code: 165.HK) was established in Hong Kong in 1997. With over 20 years of experience in cross-border asset management and private equity investment, it is a listed company in Hong Kong whose core business is alternative asset management, with China Everbright Group as its parent company. Through multiple private equity funds, venture capital funds, industry funds, mezzanine funds, funds of funds, fixed-income funds, and equity funds under its management, Everbright Limited has collaborated with investors to nurture numerous enterprises with high growth potential. In addition, aligning with the development needs of Chinese enterprises, it integrates overseas technological advantages with the Chinese market, thereby providing diversified financial services to investors in China and abroad.

Haoyue Capital was established in January 2014, with a mission to serve as a bridge connecting China’s healthcare sector with capital markets. Its research and transaction coverage spans multiple sub-sectors, including innovative medical devices, biopharmaceuticals, in vitro diagnostics (IVD) and precision medicine, healthcare services, and smart healthcare. The Haoyue Capital team comprises seasoned investment bankers with extensive experience in China’s healthcare industry. By closely monitoring market dynamics and investment trends in the healthcare sector over the long term, the firm publishes weekly healthcare investment reports and thematic research studies, offering Haoyue’s perspectives on new policies and emerging frontiers.